Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation

Gut

Volumn 65, Issue 1, 2016, Pages 134-143

  Behm, Barbara ^a   Di Fazio, Pietro ^b   Michl, Patrick ^c   Neureiter, Daniel ^d   Kemmerling, Ralf ^d   Hahn, Eckhart Georg ^a   Strobel, Deike ^a   Gress, Thomas ^c   Schuppan, Detlef ^e,f   Wissniowski, Thaddaeus Till ^a,c  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

^d PARACELSUS MEDICAL UNIVERSITY   (Austria)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 8; OLIGONUCLEOTIDE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CPG-OLIGONUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CPG ISLAND; DRUG DOSE COMPARISON; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; LIVER CELL CARCINOMA; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TREATMENT DURATION; TUMOR GROWTH; TUMOR INVASION; TUMOR VOLUME; AGONISTS; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CYTOTOXIC T LYMPHOCYTE; EVALUATION STUDY; IMMUNOLOGY; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; METABOLISM; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RABBIT; RANDOMIZATION; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; NEOPLASM TRANSPLANTATION; OLIGODEOXYRIBONUCLEOTIDES; RABBITS; RANDOM ALLOCATION; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 9; TREATMENT OUTCOME;

EID: 84955443275     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308286     Document Type: Article

References (51)

1. Hanish SI, Knechtle SJ. Liver transplantation for the treatment of hepatocellular carcinoma. Oncology (Williston Park) 2011;25:752-7.
2. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008;371:838-51.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
4. Varela M, Sala M, Llovet JM, et al. Treatment of hepatocellular carcinoma: is there an optimal strategy? Cancer Treat Rev 2003;29:99-104.
5. Bruix J, Llovet JM. HCC surveillance: who is the target population? Hepatology 2003;37:507-9.
6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
7. Georgiades CS, Hong K, Geschwind JF. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer J 2008;14:117-22.
8. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999;5:1249-55.
9. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996;8:271-80.
10. Yang WL, Nair DG, Makizumi R, et al. Heat shock protein 70 is induced in mouse human colon tumor xenografts after sublethal radiofrequency ablation. Ann Surg Oncol 2004;11:399-406.
11. Nobuoka D, Motomura Y, Shirakawa H, et al. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. Int J Oncol 2012;40:63-70.
12. Hansler J, Wissniowski TT, Schuppan D, et al. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol 2006;12:3716-21.
13. Napoletano C, Taurino F, Biffoni M, et al. RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. Int J Oncol 2008;32:481-90.
14. Wissniowski TT, Hansler J, Neureiter D, et al. Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res 2003;63:6496-500.
15. Zerbini A, Pilli M, Fagnoni F, et al. Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J Immunother 2008;31:271-82.
16. Liu Q, Zhai B, Yang W, et al. Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine. Mol Ther 2009;17:2049-57.
17. Alexandrescu DT, Ichim TE, Riordan NH, et al. Immunotherapy for melanoma: current status and perspectives. J Immunother 2010;33:570-90.
18. Moschella F, Proietti E, Capone I, et al. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Ann N Y Acad Sci 2010;1194:169-78.
19. Andersen MH, Junker N, Ellebaek E, et al. Therapeutic cancer vaccines in combination with conventional therapy. J Biomed Biotechnol 2010;2010:237623.
20. Nakai N, Hartmann G, Kishimoto S, et al. Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters. Pigment Cell Melanoma Res 2010;23:607-19.
21. Nakamoto Y, Mizukoshi E, Kitahara M, et al. Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization. Clin Exp Immunol 2011;163:165-77.
22. Kalinski P, Urban J, Narang R, et al. Dendritic cell-based therapeutic cancer vaccines: what we have and what we need. Future Oncol 2009;5:379-0.
23. Murad YM, Clay TM, Lyerly HK, et al. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol Ther 2007;7:1257-66.
24. Rothenfusser S, Hornung V, Ayyoub M, et al. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood 2004;103:2162-9.
25. Bode C, Zhao G, Steinhagen F, et al. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011;10:499-511.
26. Hansler J, Neureiter D, Wasserburger M, et al. Percutaneous US-guided radiofrequency ablation with perfused needle applicators: improved survival with the VX2 tumor model in rabbits. Radiology 2004;230:169-74.
27. Vogl TJ, Wissniowski TT, Naguib NN, et al. Activation of tumor-specific T lymphocytes after laser-induced thermotherapy in patients with colorectal liver metastases. Cancer Immunol Immunother 2009;58:1557-63.
28. Beineke A, Siebert U, Wunschmann A, et al. Immunohistochemical investigation of the cross-reactivity of selected cell markers from various species for characterization of lymphatic tissues in the harbour porpoise (Phocoena phocoena). J Comp Pathol 2001;125:311-17.
29. Kemmerling R, Stintzing S, Muhlmann J, et al. Primary testicular lymphoma: a strictly homogeneous hematological disease? Oncol Rep 2010;23:1261-7.
30. Sonoda A, Nitta N, Nitta-Seko A, et al. Time-course studies of implanted rabbit VX2 liver tumors to identify the appropriate time for starting hepatic arterial embolization in animal models. Oncology 2011;80:92-6.
31. Dromi SA, Walsh MP, Herby S, et al. Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology 2009;251:58-66.
32. den Brok MH, Sutmuller RP, Nierkens S, et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer 2006;95:896-905.
33. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-80.
34. Davila E, Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 2000;165:539-47.
35. Heckelsmiller K, Rall K, Beck S, et al. Peritumoral CpG DNA elicits a coordinated response of CD8T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 2002;169:3892-9.
36. Kageyama K, Yamamoto A, Okuma T, et al. Radiofrequency ablation of liver tumors in combination with local OK-432 injection prolongs survival and suppresses distant tumor growth in the rabbit model with intra- and extrahepatic VX2 tumors. Cardiovasc Intervent Radiol 2013;36:1383-92.
37. Hamamoto S, Okuma T, Yamamoto A, et al. Radiofrequency ablation and immunostimulant OK-432: combination therapy enhances systemic antitumor immunity for treatment of VX2 lung tumors in rabbits. Radiology 2013;267:405-13.
38. Dalpke A, Zimmermann S, Heeg K. Immunopharmacology of CpG DNA. Biol Chem 2002;383:1491-500.
39. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-60.
40. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002;168:4531-7.
41. Jolesch A, Elmer K, Bendz H, et al. Hsp70, a messenger from hyperthermia for the immune system. Eur J Cell Biol 2012;91:48-52.
42. Beere HM. "The stress of dying": the role of heat shock proteins in the regulation of apoptosis. J Cell Sci 2004;117:2641-51.
43. Nikfarjam M, Muralidharan V, Su K, et al. Patterns of heat shock protein (HSP70) expression and Kupffer cell activity following thermal ablation of liver and colorectal liver metastases. Int J Hyperthermia 2005;21:319-32.
44. Binder RJ. CD40-independent engagement of mammalian hsp70 by antigen-presenting cells. J Immunol 2009;182:6844-50.
45. Binder RJ, Kelly JB III, Vatner RE, et al. Specific immunogenicity of heat shock protein gp96 derives from chaperoned antigenic peptides and not from contaminating proteins. J Immunol 2007;179:7254-61.
46. Isbert C, Ritz JP, Roggan A, et al. Enhancement of the immune response to residual intrahepatic tumor tissue by laser-induced thermotherapy (LITT) compared to hepatic resection. Lasers Surg Med 2004;35:284-92.
47. Badie B, Berlin JM. The future of CpG immunotherapy in cancer. Immunotherapy 2013;5:1-3.
48. Dearman RJ, Cumberbatch M, Maxwell G, et al. Toll-like receptor ligand activation of murine bone marrow-derived dendritic cells. Immunology 2009;126:475-84.
49. Yamada K, Nakao M, Fukuyama C, et al. Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Sci 2010;101:188-95.
50. Manegold C, Gravenor D, Woytowitz D, et al. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3979-86.
51. Fourcade J, Kudela P, Andrade Filho PA, et al. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother 2008;31:781-91.